choline receptor partial agonist vs. sustained-release bupropion and placebo for smoking cessation. JAMA 2006; 296(1):47-55. 47. Kessler RC, Berglund PA, Borges G, Castilla-Puentes RC, Glantz MD, Jaeger SA, et al. Smoking and suicidal behaviors in the Nat
Published
Mar 2, 2010
Almetrics
Dimensions
Google Scholar
##plugins.themes.bootstrap3.article.details##
Abstract
Smoking is a chronic disease due to physical and psychological nicotine dependence and remains as the leading cause of preventable mortality. Availability of tobacco products and social approval has a great impact on consumption in the general population.
Smoking is a paradoxical problem. Although multiple cost-effective therapies are available, health practitioners are barely trained or motivated to treat
these patients. Appropriate specialized centers and health coverage for its management are also lacking.
Pharmacological therapy must be a part of an organized, interdisciplinary and multifactorial strategy, prescribed in an adequate stage of change. This article is a review of the pharmacological treatment for smoking cessation.
Keywords
smoking, tobacco, cessation, pharmacotherapy, tabaquismo, abandono, tabaco, farmacoterapia,
References
1. Guindon E, Boisclair D. Tendencias pasadas, presentes y futuras del
consumo de tabaco. Documento de trabajo No. 6 de la serie aspectos
económicos del control del tabaco. Ediciones de la Organización Mundial
de la Salud. Ginebra, Suiza. 2000.
2. Organización Mundial de la Salud. Informe OMS sobre la epidemia
mundial de tabaquismo, 2008: plan de medidas para hacer retroceder la
epidemia del tabaquismo MPOWER. Ediciones de la Organización Mundial
de la Salud. Ginebra, Suiza. 2008.
3. Ministerio de Salud y Ambiente de la Nación. Guía nacional de tratamiento de la adicción al tabaco. Ministerio de Salud y Ambiente de la Nación. Buenos Aires, Argentina. 2005.
4. Vanegas P. Políticas públicas hacia las conductas adictivas no saludables: el caso del tabaquismo en Colombia. Bogotá: Dirección Nacional de Salud Pública, Colombia. 1999.
5. Ministerio de Salud. Estudio Nacional de Factores de Riesgo de Enfermedades Crónicas ENFREC II. Bogotá: Ministerio de Salud. 1999.
6. Becerra N, Cañón M. Informe de seguimiento y comparativo 2007-2008. Consultorios Médicos Pontificia Universidad Javeriana. Bogotá: Pontificia Universidad Javeriana. 2009.
7. U.S. Department of Health and Human Services, Public Health Service.
Consecuencias del fumar en la salud: lo que significa para Ud. Atlanta: Centers of Disease Control and Prevention. 2004.
8. U.S. Department of Health and Human Services. Treating Tobacco Use and Dependence. Clinical Practice Guideline, Rockville, Maryland, U.S. Junio 2000.
9. Tobacco Advisory Group of the Royal College of Physicians. Nicotine addiction in Britain; a report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians of London; 2000. Fecha de consulta: 23 de marzo de 2008.
Disponible en: http://www.rcplondon.ac.uk/pubs/books/nicotine.
10. Institute of Medicine (US). Clearing the Smoke: Assessing the science base for tobacco harm reduction. Washington (DC): The Institute. 2001.
11. Minervini MC, Patiño CM, Zabert GE, Rondelli MP, Gómez RM, Castaños C. Tabaco o salud, el rol del médico. Inmunol Clín 1998;15(4):152-7.
12. U.S. Department of Health and Human Services. Treating Tobacco Use and Dependence. Clinical Practice Guideline, Rockville, Maryland, U.S. Update 2008.
13. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the Clinical Practice Recommendations in the AHCPR Guideline for Smoking Cessation. JAMA. 1997; 278(21):1759-66.
14. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD000146. DOI: 10.1002/14651858. CD000146.pub2.
15. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000031. DOI: 10.1002/14651858. CD000031.pub3
16. Ronckers S, Ament A. Cost-effectiveness of treatment for tobacco dependence. A sistematic review of the evidence. Economics of Tobacco Control Paper No. 5. The World Bank. Washington, DC. 2003.
17. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technology Assessment 2002; Vol. 6: No. 16.
18. Eisenberg M, Filion K, Yavin D, Bélisle P, Mottillo S, Joseph L, Gervais A, O’Loughlin J, Paradis G, Rinfret S, Pilote L. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal 2008; 179(2):135-144.
19. Lemmens V, Oenema A, Knut IK, Brug J. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. European Journal of Cancer Prevention: Issue 6 November 2008; Vol. 17:535-44.
20. Hughes JR, Shiffman S. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control. 2003;12;21-7.
21. Prochaska J, DiClemente C. Transtheoretical therapy: towards a more integrative model of change. Psychotherapy Theory Res Prac. 1982;19:276-88. 22. Prochska JO, Velicer WF, DiClemente, Fava J. Measuring processes of change: applications to the cessation of smoking. J Consult Clin Psicol. 1988; 56:520-8.
23. Jiménez-Ruiz CA, De Granda Orive JI, Solano Reina S, Carrión Valero F, Romero Palacios P, Barrueco Ferrero M. Recomendaciones para el tratamiento del tabaquismo. Arch Bronconeumol. 2003;39:514-23.
24. Raw M, Anderson P, Batra A, Dubois G, Harrington P, Hisch A, et al. WHO Europe evidence based recommendations on the treatment of tobacco dependence. Tob Control. 2002;11:44-6.
25. Jiménez-Ruiz CA, Ayesta MA, Planchuelo R, Abengozar M, Torrecilla
AM, Quintas M, et al. Recomendaciones de la Sociedad Española de
Especialistas en Tabaquismo (SEDET) sobre el tratamiento farmacológico
del tabaquismo. Prev Tab. 2001; 3(2):78-85.
26. Nides M. Update on Pharmacologic Options for Smoking Cessation Treatment. The American Journal of Medicine. Vol. 121, issue 4, Supplement, Pages S20-S31. April 2008.
27. Fagerström KO. Combined use of nicotine replacement products.
Health Values. 1994;18:15-20.
28. Foulds J, Burke M, Steinberg M, Williams J, Ziedonis D. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs.
2004; 9(1):39-53.
29. Kotlyar M. Effect of Nonnicotine Pharmacotherapy on Smoking Behavior. Pharmacotherapy. 2001;21(12):1530-48.
30. Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 1 Jul 2002;67(2):219-23.
31. Ascher JA, Cole JO, Colin JN. Bupropion: a review of its mechanism
of antidepressant activity. J Clin Psychiatry. 1995;56:395-401.
32. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology. 2003;168:347-58.
33. Roddy E. Bupropion and other non nicotine pharmacotherapies. ABC of smoking cessation. BMJ. 28 Feb 2004;328(7438):509-11.
34. Jiménez Ruiz CA, Solano S, González JM, Ruiz MJ, Flórez S, Ramos A et al. Normativa sobre el tratamiento del tabaquismo. Arch Bronconeumol. 1999; 335: 499-506.
35. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hugher AR et al. A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340: 685-691.
36. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000031.
37. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs. 2002;62(suppl 2):25-35.
38. Hays JT; Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ et. Sustained release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med. 2001;135:423-33.
39. Hurt R, Sachs A, Glover E, Offord K, Johnston J, Dale L, et al. Comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-202.
40. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban 3) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol. 2003;59:767-73.
41. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA.. A prospective safety surveillance study for bupropion sustained release in the treatment of depression. J Clin Psychiatry. Jul 1998;59(7):366-73.
42. Kaur K, Kaushal S, Chopra SC. Varenicline for smoking cessation: A
review of the literature. Current Therapeutic Research, Vol. 71, Issue 1, Feb 2010:89.
43. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch
Intern Med. Aug 2006; 14-28;166(15):1571-7.
44. Jorenby DE, Hays JT, Rigotti NA. Efficacy of varenicline an α4β2
nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):56-63.
45. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a
randomized controlled trial. JAMA. 2006 Jul 5;296(1):64-71.
46. Gonzalez D, Rennard SI, Nides M. Varenicline an á4â2 nicotinic acetylcholine receptor partial agonist vs. sustained-release bupropion and placebo for smoking cessation. JAMA 2006; 296(1):47-55.
47. Kessler RC, Berglund PA, Borges G, Castilla-Puentes RC, Glantz MD, Jaeger SA, et al. Smoking and suicidal behaviors in the National Comorbidity Survey: Replication. J Nerv Ment Dis. May 2007;195(5):369-77.
48. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation.
Cochrane Database Syst Rev. 2004; (3):CD000058.
49. Hughes JR, Stead LF, Lancaster T. Ansiolíticos para dejar de fumar
(revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008
Número 4.
consumo de tabaco. Documento de trabajo No. 6 de la serie aspectos
económicos del control del tabaco. Ediciones de la Organización Mundial
de la Salud. Ginebra, Suiza. 2000.
2. Organización Mundial de la Salud. Informe OMS sobre la epidemia
mundial de tabaquismo, 2008: plan de medidas para hacer retroceder la
epidemia del tabaquismo MPOWER. Ediciones de la Organización Mundial
de la Salud. Ginebra, Suiza. 2008.
3. Ministerio de Salud y Ambiente de la Nación. Guía nacional de tratamiento de la adicción al tabaco. Ministerio de Salud y Ambiente de la Nación. Buenos Aires, Argentina. 2005.
4. Vanegas P. Políticas públicas hacia las conductas adictivas no saludables: el caso del tabaquismo en Colombia. Bogotá: Dirección Nacional de Salud Pública, Colombia. 1999.
5. Ministerio de Salud. Estudio Nacional de Factores de Riesgo de Enfermedades Crónicas ENFREC II. Bogotá: Ministerio de Salud. 1999.
6. Becerra N, Cañón M. Informe de seguimiento y comparativo 2007-2008. Consultorios Médicos Pontificia Universidad Javeriana. Bogotá: Pontificia Universidad Javeriana. 2009.
7. U.S. Department of Health and Human Services, Public Health Service.
Consecuencias del fumar en la salud: lo que significa para Ud. Atlanta: Centers of Disease Control and Prevention. 2004.
8. U.S. Department of Health and Human Services. Treating Tobacco Use and Dependence. Clinical Practice Guideline, Rockville, Maryland, U.S. Junio 2000.
9. Tobacco Advisory Group of the Royal College of Physicians. Nicotine addiction in Britain; a report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians of London; 2000. Fecha de consulta: 23 de marzo de 2008.
Disponible en: http://www.rcplondon.ac.uk/pubs/books/nicotine.
10. Institute of Medicine (US). Clearing the Smoke: Assessing the science base for tobacco harm reduction. Washington (DC): The Institute. 2001.
11. Minervini MC, Patiño CM, Zabert GE, Rondelli MP, Gómez RM, Castaños C. Tabaco o salud, el rol del médico. Inmunol Clín 1998;15(4):152-7.
12. U.S. Department of Health and Human Services. Treating Tobacco Use and Dependence. Clinical Practice Guideline, Rockville, Maryland, U.S. Update 2008.
13. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the Clinical Practice Recommendations in the AHCPR Guideline for Smoking Cessation. JAMA. 1997; 278(21):1759-66.
14. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD000146. DOI: 10.1002/14651858. CD000146.pub2.
15. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000031. DOI: 10.1002/14651858. CD000031.pub3
16. Ronckers S, Ament A. Cost-effectiveness of treatment for tobacco dependence. A sistematic review of the evidence. Economics of Tobacco Control Paper No. 5. The World Bank. Washington, DC. 2003.
17. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technology Assessment 2002; Vol. 6: No. 16.
18. Eisenberg M, Filion K, Yavin D, Bélisle P, Mottillo S, Joseph L, Gervais A, O’Loughlin J, Paradis G, Rinfret S, Pilote L. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal 2008; 179(2):135-144.
19. Lemmens V, Oenema A, Knut IK, Brug J. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. European Journal of Cancer Prevention: Issue 6 November 2008; Vol. 17:535-44.
20. Hughes JR, Shiffman S. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control. 2003;12;21-7.
21. Prochaska J, DiClemente C. Transtheoretical therapy: towards a more integrative model of change. Psychotherapy Theory Res Prac. 1982;19:276-88. 22. Prochska JO, Velicer WF, DiClemente, Fava J. Measuring processes of change: applications to the cessation of smoking. J Consult Clin Psicol. 1988; 56:520-8.
23. Jiménez-Ruiz CA, De Granda Orive JI, Solano Reina S, Carrión Valero F, Romero Palacios P, Barrueco Ferrero M. Recomendaciones para el tratamiento del tabaquismo. Arch Bronconeumol. 2003;39:514-23.
24. Raw M, Anderson P, Batra A, Dubois G, Harrington P, Hisch A, et al. WHO Europe evidence based recommendations on the treatment of tobacco dependence. Tob Control. 2002;11:44-6.
25. Jiménez-Ruiz CA, Ayesta MA, Planchuelo R, Abengozar M, Torrecilla
AM, Quintas M, et al. Recomendaciones de la Sociedad Española de
Especialistas en Tabaquismo (SEDET) sobre el tratamiento farmacológico
del tabaquismo. Prev Tab. 2001; 3(2):78-85.
26. Nides M. Update on Pharmacologic Options for Smoking Cessation Treatment. The American Journal of Medicine. Vol. 121, issue 4, Supplement, Pages S20-S31. April 2008.
27. Fagerström KO. Combined use of nicotine replacement products.
Health Values. 1994;18:15-20.
28. Foulds J, Burke M, Steinberg M, Williams J, Ziedonis D. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs.
2004; 9(1):39-53.
29. Kotlyar M. Effect of Nonnicotine Pharmacotherapy on Smoking Behavior. Pharmacotherapy. 2001;21(12):1530-48.
30. Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 1 Jul 2002;67(2):219-23.
31. Ascher JA, Cole JO, Colin JN. Bupropion: a review of its mechanism
of antidepressant activity. J Clin Psychiatry. 1995;56:395-401.
32. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology. 2003;168:347-58.
33. Roddy E. Bupropion and other non nicotine pharmacotherapies. ABC of smoking cessation. BMJ. 28 Feb 2004;328(7438):509-11.
34. Jiménez Ruiz CA, Solano S, González JM, Ruiz MJ, Flórez S, Ramos A et al. Normativa sobre el tratamiento del tabaquismo. Arch Bronconeumol. 1999; 335: 499-506.
35. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hugher AR et al. A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340: 685-691.
36. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000031.
37. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs. 2002;62(suppl 2):25-35.
38. Hays JT; Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ et. Sustained release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med. 2001;135:423-33.
39. Hurt R, Sachs A, Glover E, Offord K, Johnston J, Dale L, et al. Comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-202.
40. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban 3) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol. 2003;59:767-73.
41. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA.. A prospective safety surveillance study for bupropion sustained release in the treatment of depression. J Clin Psychiatry. Jul 1998;59(7):366-73.
42. Kaur K, Kaushal S, Chopra SC. Varenicline for smoking cessation: A
review of the literature. Current Therapeutic Research, Vol. 71, Issue 1, Feb 2010:89.
43. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch
Intern Med. Aug 2006; 14-28;166(15):1571-7.
44. Jorenby DE, Hays JT, Rigotti NA. Efficacy of varenicline an α4β2
nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):56-63.
45. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a
randomized controlled trial. JAMA. 2006 Jul 5;296(1):64-71.
46. Gonzalez D, Rennard SI, Nides M. Varenicline an á4â2 nicotinic acetylcholine receptor partial agonist vs. sustained-release bupropion and placebo for smoking cessation. JAMA 2006; 296(1):47-55.
47. Kessler RC, Berglund PA, Borges G, Castilla-Puentes RC, Glantz MD, Jaeger SA, et al. Smoking and suicidal behaviors in the National Comorbidity Survey: Replication. J Nerv Ment Dis. May 2007;195(5):369-77.
48. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation.
Cochrane Database Syst Rev. 2004; (3):CD000058.
49. Hughes JR, Stead LF, Lancaster T. Ansiolíticos para dejar de fumar
(revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008
Número 4.
How to Cite
Becerra, N. A., Cañón, M., & Vivas, J. M. (2010). choline receptor partial agonist vs. sustained-release bupropion and placebo for smoking cessation. JAMA 2006; 296(1):47-55. 47. Kessler RC, Berglund PA, Borges G, Castilla-Puentes RC, Glantz MD, Jaeger SA, et al. Smoking and suicidal behaviors in the Nat. Universitas Medica, 51(2), 167–183. https://doi.org/10.11144/Javeriana.umed51-2.tfpa
Issue
Section
Original Articles